Scarica l'app Stockscreener
3.27
3.25%
-0.11
Dopo l'orario di chiusura:
3.26
-0.01
-0.31%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PYXS Giù?
Forum
Previsione
Pyxis Oncology Inc Borsa (PYXS) Ultime notizie
Enterprise value to revenue forward of Pyxis Oncology, Inc. – NASDAQ:PYXS - TradingView
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright By Investing.com - Investing.com Australia
Pyxis Oncology (NASDAQ: PYXS) to Launch Phase 3 Trial for MICVO in Mid-2027 Following Promising Phase 1 Results - Kalkine Media
Pyxis Oncology stock price target raised to $8 by H.C. Wainwright - Investing.com Canada
Wells Fargo raises Pyxis Oncology stock price target on MICVO data - Investing.com Canada
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell CarcinomaSlideshow (NASDAQ:PYXS) 2026-09-10 - Seeking Alpha
Wedbush raises Pyxis Oncology stock price target on trial data - Investing.com
Pyxis Oncology Slides 7% as Analysts Flag Toxicity Concerns for Lead Cancer Drug - finance.biggo.com
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug - Benzinga
Wedbush Lifts Price Target on Pyxis Oncology to $8 From $6, Keeps Outperform Rating - marketscreener.com
Pyxis Oncology shares fall 7% despite updated MICVO trial results - Yahoo Finance
PYXS: MICVO showed strong efficacy and manageable safety in advanced head and neck cancer patients - TradingView
Pyxis Oncology stock falls 7% despite positive trial data By Investing.com - Investing.com South Africa
Pyxis slides after new early-stage trial data for lead asset in head and neck cancer - TradingView
Pyxis Oncology Reports 36% Response Rate in Phase 1 MICVO Study - marketscreener.com
Pyxis Oncology Reports Promising MICVO Phase 1 Results - TipRanks
Pyxis Oncology reports 36% cORR, 6.2‑month mPFS and 79% 12‑month OS probability for MICVO in 2L+ HNSCC - TradingView
Head and neck cancer drug from Pyxis Oncology (PYXS) shows tumor responses ahead of 500-patient trial - Stock Titan
A cancer treatment showed disease control in 94% of trial patients. Pyxis plans a roughly 500-patient trial. - Stock Titan
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) - marketscreener.com
Pyxis Oncology Announces Positive Updated Data from Phase 1 - GlobeNewswire
symbol__ Stock Quote Price and Forecast - CNN
Pyxis Oncology Stock Soars Over 5% Overnight: Here's What You Need to Know - TradingView
Pyxis Oncology to present clinical data on cancer therapy By Investing.com - Investing.com South Africa
Pyxis Oncology to present clinical data on cancer therapy - Investing.com
Updated cancer-drug data will be presented Sept. 9. A Memorial Sloan Kettering expert will join Pyxis Oncology. - Stock Titan
Pyxis Oncology Names Thomas Civik CEO and Chairman Ahead of MICVO Milestones - citybiz
Pyxis Oncology Appoints Thomas Civik as CEO and Chairman of the Board - Oncodaily
Pyxis Oncology Names Thomas Civik CEO, Board Chairman - marketscreener.com
Pyxis Oncology, Inc. Announces Board Changes - marketscreener.com
Pyxis Oncology, Inc. Announces Appointment of Thomas Civik to Chief Executive Officer, Effective September 4, 2026 - marketscreener.com
Pyxis Oncology Elevates Thomas Civik to Permanent CEO - TipRanks
Pyxis Oncology names Thomas Civik as permanent CEO and chairman By Investing.com - Investing.com Canada
Pyxis Oncology names Thomas Civik as permanent CEO and chairman - Investing.com
Pyxis Oncology (PYXS) CEO receives 2.5M options at $3.89 - Stock Titan
Pyxis Oncology Appoints Thomas Civik CEO and Chairman as John Flavin Becomes Lead Independent Director - quiverquant.com
New CEO-chair steps in at Pyxis Oncology (PYXS) ahead of 2026 cancer drug data - Stock Titan
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board - Stock Titan
PYXS Rallies As Pyxis Oncology Extends Cash Runway To 2027 - timothysykes.com
PYXS Jumps As Pyxis Oncology Extends Cash Runway, Eyes MICVO Data - timothysykes.com
Pyxis Oncology stock gains on MICVO conference catalysts - ad-hoc-news.de
Pyxis Oncology Inc (PYXS) Peer Comparison – Compare with Others - Value Research
Pyxis Oncology Inc (PYXS) Key Financial Ratios – Valuation, Profitability & More - Value Research
PYXS Stock Price, Quote & Chart - ChartMill
Pyxis Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Pyxis Oncology Inc (PYXS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Pyxis Oncology, Inc. SEC Filing (Aug 28, 2026) - Stock Titan
Pyxis Oncology Inc (NASDAQ: PYXS) Share Price, PYXS Stock News, PYXS Share Price & Updates - Kalkine
Pyxis Oncology files prospectus for 39.2M share sale by existing holders - scanx.trade
Pyxis Oncology (PYXS) awards director options at $3.12 - Stock Titan
Q3 EPS Estimates for Pyxis Oncology Raised by HC Wainwright - MarketBeat
Pyxis Oncology FY2030 EPS Forecast Reduced by HC Wainwright - MarketBeat
HC Wainwright Reiterates Buy Rating for Pyxis Oncology (NASDAQ:PYXS) - MarketBeat
H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Pyxis Oncology (PYXS) Holds Steady at $3.01 as Consolidation TightensWyckoff Accumulation - vinanet.vn
PYXS Q1 2026 Earnings: Modest EPS Beat Points to Cost Discipline for Clinical-Stage Oncology FirmDividend Earnings Report - vinanet.vn
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology (PYXS) Gets a Buy from Wells Fargo - The Globe and Mail
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Pyxis Oncology (PYXS) CEO receives 250,956-share performance-based option grant - Stock Titan
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Analysts Have Conflicting Sentiments on These Healthcare Companies: Candel Therapeutics (CADL), LENSAR (LNSR) and Pyxis Oncology (PYXS) - The Globe and Mail
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):